Drug Trial Radar · NCT01965912
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 2013
Primary completion
Jan 4, 2023
Study completion Jan 4, 2023
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Oct 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a single-cohort, interventional, open-label trial to evaluate long-term neurocognitive (NC) outcomes in children aged 4 to 5 years with phenylketonuria (PKU) treated with Kuvan® and Phenylalanine-restricted diet over a period of 7 years.
Conditions
- Phenylketonuria
Interventions
Kuvan®Drug
Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Full Scale Intelligence Quotient (FSIQ) Score of the Wechsler Intelligence Scale for Children (WISC)-IVTime frame: Year 7
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Research site
Munich, Germany
Research site
Münster, Germany
Research site
Bologna, Italy
Research site - Bambino Gesu
Roma, Italy
Research site - La Sapienza
Roma, Italy
Research Site
Barcelona, Spain
Research site
Murcia, Spain
Research site
Santiago de Compostela, Spain
Research site
Birmingham, United Kingdom
Research site
Bristol, United Kingdom
Research Site - Evelina
London, United Kingdom
Research site - GOSH
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.